PL1625166T3 - Przeciwciała przeciwko masp-2 - Google Patents
Przeciwciała przeciwko masp-2Info
- Publication number
- PL1625166T3 PL1625166T3 PL04732276T PL04732276T PL1625166T3 PL 1625166 T3 PL1625166 T3 PL 1625166T3 PL 04732276 T PL04732276 T PL 04732276T PL 04732276 T PL04732276 T PL 04732276T PL 1625166 T3 PL1625166 T3 PL 1625166T3
- Authority
- PL
- Poland
- Prior art keywords
- masp
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300716 | 2003-05-12 | ||
| EP04732276.3A EP1625166B1 (en) | 2003-05-12 | 2004-05-12 | Antibodies to masp-2 |
| PCT/DK2004/000338 WO2004106384A1 (en) | 2003-05-12 | 2004-05-12 | Antibodies to masp-2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1625166T3 true PL1625166T3 (pl) | 2015-08-31 |
Family
ID=33483731
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11172040T PL2374819T3 (pl) | 2003-05-12 | 2004-05-12 | Przeciwciała przeciwko MASP-2 |
| PL04732276T PL1625166T3 (pl) | 2003-05-12 | 2004-05-12 | Przeciwciała przeciwko masp-2 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11172040T PL2374819T3 (pl) | 2003-05-12 | 2004-05-12 | Przeciwciała przeciwko MASP-2 |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9096676B2 (pl) |
| EP (2) | EP2374819B1 (pl) |
| CN (1) | CN1798769A (pl) |
| CY (2) | CY1116506T1 (pl) |
| DK (2) | DK2374819T3 (pl) |
| ES (2) | ES2629344T3 (pl) |
| HU (2) | HUE034760T2 (pl) |
| PL (2) | PL2374819T3 (pl) |
| PT (2) | PT1625166E (pl) |
| SI (2) | SI2374819T1 (pl) |
| WO (1) | WO2004106384A1 (pl) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| ES2629344T3 (es) | 2003-05-12 | 2017-08-08 | Helion Biotech Aps | Anticuerpos contra la MASP-2 |
| US20060018896A1 (en) * | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| AU2011265532B2 (en) * | 2004-06-10 | 2014-04-24 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8951522B2 (en) | 2011-04-08 | 2015-02-10 | University Of Leicester | Methods for treating conditions associated with MASP-2 dependent complement activation |
| ES2601497T3 (es) * | 2004-06-10 | 2017-02-15 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| AU2013201561B2 (en) * | 2004-06-10 | 2016-03-31 | Omeros Corporation | Methods for treating conditions associated with MASP-2-dependent complement activation |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8859209B2 (en) | 2006-01-12 | 2014-10-14 | Carviar Aps | Reimmunization and antibody design |
| WO2007095154A2 (en) * | 2006-02-10 | 2007-08-23 | The Brigham And Women's Hospital, Inc. | Lectin complement pathway assays and related compositions and methods |
| EP2463306A1 (en) | 2006-05-02 | 2012-06-13 | Carviar ApS | Method for immunizing an avian species |
| CA2723219A1 (en) * | 2008-05-09 | 2009-11-12 | Abbott Gmbh & Co. Kg | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
| CA2777845C (en) * | 2009-10-16 | 2017-08-01 | Omeros Corporation | Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation |
| US9644035B2 (en) | 2011-04-08 | 2017-05-09 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| AU2013201779B2 (en) * | 2011-05-04 | 2016-01-07 | Omeros Corporation | Compositions for inhibiting MASP-2 dependent complement activation |
| CA3025762C (en) * | 2011-05-04 | 2021-11-09 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| US20140363433A1 (en) | 2013-03-15 | 2014-12-11 | Omeros Corporation | Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same |
| AU2014229020B2 (en) * | 2013-03-15 | 2017-09-28 | Omeros Corporation | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same |
| CN103614341B (zh) * | 2013-09-02 | 2016-07-13 | 杨旸 | 抗甘露糖结合凝聚素的单克隆抗体及试剂盒 |
| PT3057993T (pt) * | 2013-10-17 | 2020-11-19 | Omeros Corp | Métodos de tratamento das condições associadas à ativação do complemento dependente do masp-2 |
| KR20170091661A (ko) * | 2014-11-25 | 2017-08-09 | 어플라이드 머티어리얼스, 인코포레이티드 | 기판 캐리어 및 퍼지 챔버 환경 제어들을 이용하는 기판 프로세싱 시스템들, 장치, 및 방법들 |
| EP3400012A4 (en) | 2016-01-05 | 2019-12-11 | University Of Leicester | PROCESS FOR INHIBITING FIBROSIS IN A NEEDED SUBJECT |
| SG11201808242UA (en) | 2016-03-31 | 2018-10-30 | Omeros Corp | Methods for inhibiting angiogenesis in a subject in need thereof |
| JOP20190068A1 (ar) * | 2016-10-13 | 2019-04-01 | Omeros Corp | طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي |
| US11007254B2 (en) | 2016-10-17 | 2021-05-18 | Musc Foundation For Research Development | Compositions and methods for treating central nervous system injury |
| TWI818919B (zh) | 2017-08-15 | 2023-10-21 | 美商歐米諾斯公司 | 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法 |
| EA202190106A1 (ru) * | 2018-06-22 | 2021-04-13 | Омерос Корпорейшн | Композиции и способы ингибирования masp-2 для лечения различных тромботических заболеваний и расстройств |
| GB2583560A (en) | 2018-12-11 | 2020-11-04 | Admirx Inc | Fusion protein constructs for complement associated disease |
| JP7667091B2 (ja) | 2019-05-07 | 2025-04-22 | バイエル・アクチエンゲゼルシヤフト | Ｍａｓｐ阻害化合物およびその使用 |
| TWI834025B (zh) | 2020-03-06 | 2024-03-01 | 美商奥默羅斯公司 | 用於治療和/或預防冠狀病毒誘導的急性呼吸窘迫症候群的抑制masp-2的方法 |
| US20240010684A1 (en) | 2020-11-04 | 2024-01-11 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| EP4011904A1 (en) | 2020-12-14 | 2022-06-15 | Bayer Aktiengesellschaft | Masp inhibitory compounds and uses thereof |
| CN115215937B (zh) | 2021-04-15 | 2023-05-26 | 上海麦济生物技术有限公司 | 抗人masp-2抗体及其制备方法和应用 |
| IL309231A (en) * | 2021-06-08 | 2024-02-01 | Shanghai Jemincare Pharmaceuticals Co Ltd | ANTI-MASP-2 antibody and its use |
| US20240309113A1 (en) * | 2021-06-30 | 2024-09-19 | Suzhou Transcenta Therapeutics Co., Ltd. | Novel anti-masp-2 antibodies |
| CN116615544A (zh) * | 2021-12-10 | 2023-08-18 | 舒泰神（北京）生物制药股份有限公司 | 特异性识别masp2的抗体及其应用 |
| EP4493597A1 (en) * | 2022-03-18 | 2025-01-22 | Inmagene Pte. Ltd. | Masp-2-targetting antibodies and uses thereof |
| US12216123B2 (en) | 2023-04-25 | 2025-02-04 | Nuvance Health | Extracellular vesicle derived MASP-2 directed cancer treatment methods |
| WO2025153000A1 (zh) * | 2024-01-17 | 2025-07-24 | 信立泰(成都)生物技术有限公司 | 一种抗masp2抗体或其抗原结合片段及用途 |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US558767A (en) | 1896-04-21 | Oyster-dredger | ||
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4394370A (en) | 1981-09-21 | 1983-07-19 | Jefferies Steven R | Bone graft material for osseous defects and method of making same |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4526909A (en) | 1984-01-09 | 1985-07-02 | Regents Of The University Of California | Polymethylmethacrylate delivery system for bone morphogenetic protein |
| US4563489A (en) | 1984-02-10 | 1986-01-07 | University Of California | Biodegradable organic polymer delivery system for bone morphogenetic protein |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPH0662679B2 (ja) | 1985-06-21 | 1994-08-17 | 新田ゼラチン株式会社 | 組織親和性コラ−ゲンとその製法 |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US5270199A (en) | 1987-08-20 | 1993-12-14 | The Children's Medical Center Corporation | Human mannose-binding protein |
| JP3046318B2 (ja) | 1987-12-15 | 2000-05-29 | ジーン・シアーズ・ピーティーワイ・リミテッド | リボザイム |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| ES2247204T3 (es) | 1994-01-31 | 2006-03-01 | Trustees Of Boston University | Bancos de anticuerpos policlonales. |
| US5856121A (en) | 1994-02-24 | 1999-01-05 | Case Western Reserve University | Growth arrest homebox gene |
| JPH07238100A (ja) | 1994-02-25 | 1995-09-12 | Sumitomo Electric Ind Ltd | ヒトのｍａｓｐに対するモノクローナル抗体 |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6492332B1 (en) | 1995-12-12 | 2002-12-10 | Omeros Corporation | Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation |
| AU4467396A (en) | 1994-12-12 | 1996-07-10 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US6008017A (en) | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
| US6969601B2 (en) | 1997-04-03 | 2005-11-29 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US5955309A (en) | 1997-06-18 | 1999-09-21 | Smithkline Beecham Corporation | Polynucleotide encoding G-protein coupled receptor (H7TBA62) |
| US6297024B1 (en) | 1998-10-15 | 2001-10-02 | Cell Activation, Inc. | Methods for assessing complement activation |
| US7273925B1 (en) | 1998-12-15 | 2007-09-25 | Brigham And Women's Hospital, Inc. | Methods and products for regulating lectin complement pathway associated complement activation |
| JP2002532079A (ja) | 1998-12-15 | 2002-10-02 | ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド | 補体活性化に関連するレクチン補体経路を調節するための方法および産物 |
| US6235494B1 (en) | 1999-02-08 | 2001-05-22 | The Scripps Research Institute | Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates |
| CA2296792A1 (en) | 1999-02-26 | 2000-08-26 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU3395900A (en) | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
| AU3633000A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
| JP2002544286A (ja) | 1999-05-14 | 2002-12-24 | ティール，ステフェン | 免疫反応が十分に発揮し得ない個体の治療におけるマンナン結合性レクチン（ｍｂｌ）の新規適用 |
| JP2003505427A (ja) | 1999-07-21 | 2003-02-12 | オメロス コーポレイション | 疼痛、炎症および軟骨分解の抑制のための溶液および方法 |
| WO2001010902A2 (en) | 1999-08-11 | 2001-02-15 | Curagen Corporation | Nucleoc acids and secreted polypeptides encoded thereby |
| CA2380979A1 (en) | 1999-08-13 | 2001-02-22 | Brigham And Women's Hospital, Inc. | Inhibitors of the lectin complement pathway (lcp) and their use |
| WO2001040451A2 (en) | 1999-12-02 | 2001-06-07 | Jens Christian Jensenius | Masp-3, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| EP2026073B1 (en) | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| DK1303591T3 (da) | 2000-07-13 | 2009-11-02 | Helion Biotech Aps | MASP-2, et komplementfikserende enzym, og anvendelser af det |
| US20020094332A1 (en) | 2001-01-18 | 2002-07-18 | Alexion Pharmaceuticals | Method of prophylaxis against large myocardial infractions |
| CA2454562A1 (en) | 2001-07-26 | 2003-02-06 | Alexion Pharmaceuticals, Inc. | Method of improving cognitive function |
| CA2473786A1 (en) | 2002-01-22 | 2003-07-31 | Alexion Pharmaceuticals, Inc. | Method of prophylaxis against large myocardial infarctions |
| MXPA04007124A (es) | 2002-02-01 | 2004-10-29 | Omeros Corp | Composiciones y metodos para la inhibicion sistemica de la degradacion del cartilago. |
| US7538195B2 (en) * | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
| AU2003270330B2 (en) | 2002-09-06 | 2009-07-30 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component C5 |
| EP1570075A2 (en) | 2002-12-03 | 2005-09-07 | Aarhus Universitet | Method for determing predisposition to manifestation of immune system related diseases |
| US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| MXPA05008570A (es) | 2003-02-21 | 2005-11-04 | Tanox Inc | Metodos para la prevencion y tratamiento de danos tisulares asociados con una lesion por isquemia-reperfusion. |
| ES2629344T3 (es) * | 2003-05-12 | 2017-08-08 | Helion Biotech Aps | Anticuerpos contra la MASP-2 |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| JP2007504805A (ja) | 2003-09-05 | 2007-03-08 | ナットイムネ・アクティーゼルスカブ | Ｍａｓｐ−２結晶構造およびその使用 |
| AU2005250499B2 (en) * | 2004-06-03 | 2011-12-08 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| GB0412966D0 (en) | 2004-06-10 | 2004-07-14 | Univ Leicester | Genetically modified non-human mammals and cells |
| ES2601497T3 (es) | 2004-06-10 | 2017-02-15 | Omeros Corporation | Métodos para tratar afecciones asociadas con la activación del complemento dependiente de MASP-2 |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| LT3339445T (lt) * | 2006-09-08 | 2020-10-26 | Abbvie Bahamas Ltd. | Baltymai, suryšantys interleukiną 13 |
-
2004
- 2004-05-12 ES ES11172040.5T patent/ES2629344T3/es not_active Expired - Lifetime
- 2004-05-12 DK DK11172040.5T patent/DK2374819T3/en active
- 2004-05-12 EP EP11172040.5A patent/EP2374819B1/en not_active Expired - Lifetime
- 2004-05-12 PL PL11172040T patent/PL2374819T3/pl unknown
- 2004-05-12 SI SI200432396T patent/SI2374819T1/sl unknown
- 2004-05-12 US US10/556,509 patent/US9096676B2/en active Active
- 2004-05-12 PL PL04732276T patent/PL1625166T3/pl unknown
- 2004-05-12 PT PT47322763T patent/PT1625166E/pt unknown
- 2004-05-12 CN CNA2004800155204A patent/CN1798769A/zh active Pending
- 2004-05-12 PT PT111720405T patent/PT2374819T/pt unknown
- 2004-05-12 WO PCT/DK2004/000338 patent/WO2004106384A1/en not_active Ceased
- 2004-05-12 HU HUE11172040A patent/HUE034760T2/en unknown
- 2004-05-12 ES ES04732276.3T patent/ES2541134T3/es not_active Expired - Lifetime
- 2004-05-12 EP EP04732276.3A patent/EP1625166B1/en not_active Expired - Lifetime
- 2004-05-12 HU HUE04732276A patent/HUE024996T2/en unknown
- 2004-05-12 DK DK04732276.3T patent/DK1625166T3/en active
- 2004-05-12 SI SI200432248T patent/SI1625166T1/sl unknown
-
2015
- 2015-06-19 US US14/745,247 patent/US10189909B2/en not_active Expired - Lifetime
- 2015-07-02 CY CY20151100572T patent/CY1116506T1/el unknown
-
2017
- 2017-06-22 CY CY20171100658T patent/CY1119106T1/el unknown
-
2018
- 2018-12-04 US US16/209,255 patent/US11008404B2/en not_active Expired - Fee Related
-
2020
- 2020-01-07 US US16/736,626 patent/US11008405B2/en not_active Expired - Fee Related
- 2020-02-20 US US16/796,179 patent/US20200199252A1/en not_active Abandoned
-
2021
- 2021-02-22 US US17/181,983 patent/US11225526B2/en not_active Expired - Lifetime
- 2021-03-16 US US17/203,396 patent/US20210221913A1/en not_active Abandoned
-
2022
- 2022-06-28 US US17/851,944 patent/US20230058435A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11008405B2 (en) | 2021-05-18 |
| US20210261688A1 (en) | 2021-08-26 |
| ES2541134T3 (es) | 2015-07-16 |
| EP1625166B1 (en) | 2015-04-08 |
| DK2374819T3 (en) | 2017-06-06 |
| EP2374819B1 (en) | 2017-03-22 |
| US9096676B2 (en) | 2015-08-04 |
| SI2374819T1 (sl) | 2017-09-29 |
| ES2629344T3 (es) | 2017-08-08 |
| CN1798769A (zh) | 2006-07-05 |
| CY1119106T1 (el) | 2018-02-14 |
| US20070009528A1 (en) | 2007-01-11 |
| HUE024996T2 (en) | 2016-01-28 |
| US10189909B2 (en) | 2019-01-29 |
| US20230058435A1 (en) | 2023-02-23 |
| PT1625166E (pt) | 2015-08-20 |
| EP2374819A1 (en) | 2011-10-12 |
| US20210221913A1 (en) | 2021-07-22 |
| US11008404B2 (en) | 2021-05-18 |
| US20200199252A1 (en) | 2020-06-25 |
| WO2004106384A1 (en) | 2004-12-09 |
| HUE034760T2 (en) | 2018-02-28 |
| US20160096897A1 (en) | 2016-04-07 |
| US20190144564A1 (en) | 2019-05-16 |
| US20200216566A1 (en) | 2020-07-09 |
| CY1116506T1 (el) | 2017-03-15 |
| PL2374819T3 (pl) | 2017-09-29 |
| US11225526B2 (en) | 2022-01-18 |
| PT2374819T (pt) | 2017-07-04 |
| EP1625166A1 (en) | 2006-02-15 |
| DK1625166T3 (en) | 2015-07-13 |
| SI1625166T1 (sl) | 2015-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL1625166T3 (pl) | Przeciwciała przeciwko masp-2 | |
| EP1616881A4 (en) | ANTI-MPL ANTIBODIES | |
| PT1599504E (pt) | Anticorpo modificado | |
| GB0426043D0 (en) | Antibodies | |
| IL202682A0 (en) | Interleukin-10 antibodies | |
| EP1648512A4 (en) | ANTI-CD19 ANTIBODIES | |
| IL175773A0 (en) | Anti-igfr1 antibody therapeutic combinations | |
| GB0305702D0 (en) | Bispecific antibodies | |
| IL181575A0 (en) | Anti-ox40l antibodies | |
| GB0420044D0 (en) | Antibodies to m-csf | |
| IL228032A0 (en) | Antibodies | |
| IL173557A0 (en) | Variable antibodies | |
| SI1587542T1 (sl) | Uporaba anti-cd100 protiteles | |
| GB0420466D0 (en) | Anti-glucan antibodies | |
| AU2003218456A8 (en) | Antibodies that specifically bind to gmad | |
| EP1598368A4 (en) | ANTI-PCI neutralizing ANTIBODY | |
| ZA200701952B (en) | Anti-OX40L antibodies | |
| GB0306618D0 (en) | Antibody | |
| IL172511A0 (en) | Specific human antibodies | |
| GB0317974D0 (en) | Novel antibodies | |
| GB0329711D0 (en) | Antibodies | |
| GB0413479D0 (en) | Novel antibodies | |
| GB0319118D0 (en) | Variable antibodies | |
| GB0319345D0 (en) | Variable antibodies | |
| GB0217742D0 (en) | Novel antibodies |